Saturday, February 9, 2019
Program is subject to change
7:00 am | Registration and Continental Breakfast |
7:50 | Welcome and Overview / Pre-Program Test Philip J. Rosenfeld, MD, PhD, Harry W. Flynn, Jr., MD, and Thomas A. Albini, MD |
Session I: Aging, Disease Pathogenesis, and Imaging Moderators: Philip J. Rosenfeld, MD, PhD and Zohar Yehoshua, MD, MHA |
|
8:00 | Metabolic Networks and the RPE-Photoreceptor Ecosystem in Aging and Degeneration Philip Luthert, MBBS |
8:08 | Ultrahigh Speed OCTA for Assessing Choricapillaris Flow Impairment James G. Fujimoto, PhD |
8:16 | Challenges in Imaging the Choriocapillaris Richard F. Spaide, MD |
8:24 | Choriocapillaris Quantification with Phansalkar's Local Thresholding: Do's and Don'ts Zhongdi Chu, PhD |
8:32 | Choriocapillaris in Myopia SriniVas R. Sadda, MD |
8:40 | Choroidal Vessel Imaging and Quantification Ruikang (Ricky) Wang, PhD |
8:48 | The Choroid in AMD: Connecting the Dots Philip J. Rosenfeld, MD, PhD |
8:56 | Deep Learning and Reticular Pseudodrusen Emily Y. Chew, MD |
Session II: Retinal Diseases and Functional Endpoints Moderators: Thomas A. Albini, MD and Jorge A. Fortun, MD |
|
9:04 | MacTel2 as a “Serine/Ceramide-Opathy” Martin Friedlander, MD, PhD |
9:12 | Epidemiology of Common Retinal Diseases in Retina Practices in the United States Andrew A. Moshfeghi, MD, MBA |
9:20 | Functional Imaging of Mitochondria in Retinal Diseases Rishi P. Singh, MD |
9:28 | Novel Analytics to Examine Impact of Fluctuations in Retinal Thickness on Visual Outcomes Usha Chakravarthy, MD |
9:36 | Drusen and Retinal Diseases Lawrence A. Yannuzzi, MD |
9:44 | Integrating Microperimetry into Clinical Trials of Nonexudative AMD Nadia Waheed, MD |
9:52 | Rod-and-Cone-Mediated Vision in Eyes with Hyperreflective Foci: An Outcome Measure for Oil Spill Trials? Christine A. Curcio, PhD |
10:00 | Normal and Low Luminance Quantitative Contrast Sensitivity: A Novel Functional Endpoint for Rapid Measurement of Spatial Contrast Sensitivity Functions in Dry AMD Karl G. Csaky, MD, PhD |
Session III: AMD II Moderators: Philip J. Rosenfeld, MD, PhD and Raquel Goldhardt, MD |
|
10:08 | Retina Trends – A VC’s Perspective Emmett T. Cunningham, Jr., MD, PhD, MPH |
10:16 | Update in Hemera’s Gene Therapy Programs Jay S. Duker, MD |
10:24 | Kamuvudines for AMD: The Saga Continues Jayakrishna Ambati, MD |
10:32 | Phase 1 Results of a Systemic Antisense Inhibitor of Complement Factor B for Geographic Atrophy Sunil S. Patel, MD, PhD |
10:40 | Update on FHTR2163 (anti-HtrA1) for Dry AMD Vrinda Hershberger, MD, PhD |
10:48 | Update on Elamipretide for the Treatment of AMD Scott W. Cousins, MD |
10:56 | Phase 2 Study Results of Risuteganib in Dry AMD Peter K. Kaiser, MD |
11:04 | Risuteganib for the Treatment of Dry AMD: Structure/Function Correlations Glenn J. Jaffe, MD |
11:12 | Update on Brimonidine Intravitreal Implant for Dry AMD Ryan Rich, MD |
11:20 | C3 inhibition in Geographic Atrophy Cedric G. Francois, MD, PhD |
Session IV: AMD III Moderators: Harry W. Flynn, Jr., MD and Luis J. Haddock, MD |
|
11:28 | PROCON Year 2 Results Jeffrey S. Heier, MD |
11:36 | Non-Neovascular Exudative Age Related Macular Degeneration: How to Unmask the Masquerader David Sarraf, MD |
11:44 | Update on Stem Cell Therapies for AMD Amir H. Kashani, MD, PhD |
11:52 | Unregulated Stem Cells for Ocular Disease: What Happened after the NEJM Publication Thomas A. Albini, MD |
12:00pm | Retinal Implants: Where Are We Now? Jean-François Korobelnik, MD |
12:08 | Advanced Retinal Implants Mark S. Humayun, MD, PhD |
12:16 | Lunch |
Session V: Macular Neovasculation in AMD and PCV Moderators: Philip J. Rosenfeld, MD, PhD and Luis J. Haddock, MD |
|
1:16 | The Importance of MNV Type Classification in the Interpretation of the Results of Clinical Trials Giovanni Staurenghi, MD |
1:24 | Detection of Non-Exudative Subclinical MNV in AMD from Structural OCT Scans Using Deep Learning Aaron Y. Lee, MD |
1:32 | AI Based Fluid Quantification on Serial OCT Images from a Patient Self-operated Home OCT Device Anat Loewenstein, MD |
1:40 | Automated Volumetric Assessment of Subclinical Non-Exudative MNV Using SS-OCTA Luis de Sisternes, PhD |
1:48 | Rotational 3D OCTA Giuseppe Querques, MD, PhD |
1:56 | Diagnosis of PCV Using SS-OCTA Hiroko Terasaki, MD, PhD |
2:04 | Volume Rendering of OCTA in PCV K. Bailey Freund, MD |
2:12 | A Comparison Study of Polypoidal Choroidal Vasculopathy Imaged with ICGA and SS-OCTA Seung-Young Yu, MD |
2:20 | Longitudinal Changes in Subclinical PCV Gemmy Cheung, MBBS, FRCOphth, FAMS, MCI |
2:28 | Longitudinal Observations of PCV Using SS-OCTA Fenghua Wang, MD |
Session VI: Treatments for Neovasculation in AMD and ROP Moderators: Thomas A. Albini, MD and Ninel Z. Gregori, MD |
|
2:36 | Immunology of Gene Therapy Janet L. Davis, MD |
2:44 | Phase 1 study of Intravitreal Gene Therapy with DVM-022 for Neovascular AMD (OPTIC Trial) David S. Boyer, MD |
2:52 | RGX-314 Gene Therapy for wAMD and Diabetic Retinopathy Jeffrey S. Heier, MD |
3:00 | Treatment of Newly Diagnosed and Treatment Resistant Neovascular AMD with the Oral CCR3 Inhibitor ALK4290 Michael W. Stewart, MD |
3:08 | Results of the Phase I/II SUSHI Study of Intravitreal RBM-007 in Exudative AMD Quan Dong Nguyen, MD, MSc |
3:16 | Update on Phase 1b and Phase 2 Studies of KSI-301: A Novel Anti-VEGF Antibody Biopolymer Conjugate with Potential for Extended Durability in Wet AMD Diana V. Do, MD |
3:24 | Results of the Opthea OPT-302 Phase 2b Study: Combined VEGF-C / VEGF-D Suppression for nvAMD Pravin U. Dugel, MD |
3:32 | Phase 2 LADDER Trial Using the Port Delivery System with Ranibizumab: End of Study, Long-term Follow-up Results Carl D. Regillo, MD |
3:40 | Faricimab Update Karl G. Csaky, MD, PhD |
3:48 | Brolucizumab Update Lawrence J. Singerman, MD |
3:56 | Do We Need More VEGF Blockade?- The Rationale for a Clinical Trial Testing High-Dose Aflibercept David M. Brown, MD |
4:04 | Update on ROP and Anti-VEGF Clinical Trials Darius M. Moshfeghi, MD |
Session VII: Diabetes Moderators: Harry W. Flynn, Jr. MD and Justin H. Townsend, MD |
|
4:12 | Effect of Industry Funding on Abstract Bias in the Literature for Intravitreal Pharmacotherapy for Retinal Vascular Disease Jayanth Sridhar, MD |
4:20 | DRCR Retina Network Trials and Real World Experience Jennifer Sun, MD |
4:28 | Diabetic Retinopathy: Is a New Classification on the Way? Lee M. Jampol, MD |
4:36 | Artificial Intelligence Assisted Approaches for Diabetic Retinopathy Screening Michael S. Ip, MD |
4:44 | The Pattern and Density of Retinal Capillary Plexuses from the Fovea to the Periphery Using SS-OCTA Ramin Tadayoni, MD, PhD |
4:52 | Wide-field SS-OCTA is Better than FA in Detecting Capillary Dropout, Neovascularization and IRMA in Diabetic Retinopathy Toshinori Murata, MD, PhD |
5:00 | Widefield SS-OCTA in Diabetic Retinopathy Harry W. Flynn, Jr. MD |
5:08 | Development of DME in Fellow Eyes from VIVID/VISTA Dilsher Dhoot, MD |
5:16 | Intravitreal Aflibercept for Moderately Severe to Severe Non-Proliferative Diabetic Retinopathy (NPDR): 2-Year Outcomes of the Phase 3 PANORAMA Study Charles C. Wykoff, MD, PhD |
Session VIII: Diabetes, Uveitis, and Retinal Degenerations Moderator: Philip J. Rosenfeld, MD, PhD and Thomas A. Albini, MD |
|
5:24 | A Novel Implant for Delivering Low-Dose Extended Release Dexamethasone for Macular Edema Elias Reichel, MD |
5:32 | The Oculis OCS-01 Phase 1/2 Study: An Effective Topical Therapeutic for DME Pravin U. Dugel, MD |
5:40 | Front-line Local Therapies for Uveitis: From Clinical Trials to Practice Steven Yeh, MD |
5:48 | Treatments and Clinical Trials in Inherited Retinal Degenerations Byron L. Lam, MD |
5:56 | Phase 2 1-year Results of the JCyte Trial for Retinitis Pigmentosa David S. Boyer, MD |
6:04 | Results of a Clinical Trial Investigating N-acetylcysteine in Retinitis Pigmentosa Peter A. Campochiaro, MD |
6:12 | Post-Program Test and Closing Remarks |
6:20 | Adjourn/Cocktail Reception |